Technology is changing the way we think about drug treatment efficacy and the practice of medicine. Sensor technologies are rapidly evolving to measure more and more body functions and many aspects of patient’s daily life. Sensors produce vast amounts of data and we leverage advanced analytics to gain transformative endpoints for our clinical trials. These novel digital endpoints have begun to clarify health benefits in ways that previously were unmeasurable.
Clinical research at NIBR represents the early evaluation of drugs in humans with and without disease in established or new indications. As such, the inclusion of digital endpoints in NIBR studies aims to deepen and broaden our understanding of patient burden, disease progression, and treatment response, in the earliest stages of the Novartis clinical drug development process.
Our group in NIBR is dedicated to develop those new digital endpoints by combining emerging technologies and advanced analytics. We are unleashing the power of data and technology to help patients, lower the burden of study participants, create clinically meaningful and sensitive outcomes and advance our medicines.